Literature DB >> 7429072

Reinitiation of DNA synthesis in postmitotic nuclei of myotubes by virus-mediated fusion with embryonic fibroblasts.

I A Schwab, O Luger.   

Abstract

Myotubes, whose nuclei have stopped DNA synthesis were fused with replicative embryonic fibroblasts. In heterokaryons the postmitotic muscle nuclei resumed DNA synthesis. Incorporation of radioactive thymidine into muscle, and also into fibroblast nuclei was dependent upon the time elapsed between virus-mediated fusion and administration of radioactive thymidine. Whereas incorporation into fibroblast nuclei diminished with time, there was an early increase of labelling into muscle nuclei followed by a decrease of incorporation of 3H thymidine. DNA synthesis was also dependent upon the ratio of noncycling (muscle) to cycling (fibroblast) nuclei. There was a greater incorporation of 3H thymidine into muscle and fibroblast nuclei in myotubes containing larger numbers of fibroblast nuclei. A model is discussed for the control of DNA synthesis in polykaryocytes derived from fusion of cycling and noncycling cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7429072     DOI: 10.1111/j.1432-0436.1980.tb01063.x

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  3 in total

1.  Heterokaryon analysis of muscle differentiation: regulation of the postmitotic state.

Authors:  C H Clegg; S D Hauschka
Journal:  J Cell Biol       Date:  1987-08       Impact factor: 10.539

2.  In vitro differentiation of rhabdomyosarcomas induced by nickel or by Moloney murine sarcoma virus.

Authors:  P Nanni; G Azzarello; L Tessarollo; C De Giovanni; P L Lollini; G Nicoletti; K Scotlandi; L Landuzzi; M Panozzo; E D'Andrea
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

Review 3.  Restoring the Cell Cycle and Proliferation Competence in Terminally Differentiated Skeletal Muscle Myotubes.

Authors:  Deborah Pajalunga; Marco Crescenzi
Journal:  Cells       Date:  2021-10-14       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.